Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

448 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Peptides-Coated Oncolytic Vaccines for Cancer Personalized Medicine.
Feola S, Russo S, Martins B, Lopes A, Vandermeulen G, Fluhler V, De Giorgi C, Fusciello M, Pesonen S, Ylösmäki E, Antignani G, Chiaro J, Hamdan F, Feodoroff M, Grönholm M, Cerullo V. Feola S, et al. Among authors: martins b. Front Immunol. 2022 Apr 14;13:826164. doi: 10.3389/fimmu.2022.826164. eCollection 2022. Front Immunol. 2022. PMID: 35493448 Free PMC article.
Personalized Cancer Vaccine Platform for Clinically Relevant Oncolytic Enveloped Viruses.
Ylösmäki E, Malorzo C, Capasso C, Honkasalo O, Fusciello M, Martins B, Ylösmäki L, Louna A, Feola S, Paavilainen H, Peltonen K, Hukkanen V, Viitala T, Cerullo V. Ylösmäki E, et al. Among authors: martins b. Mol Ther. 2018 Sep 5;26(9):2315-2325. doi: 10.1016/j.ymthe.2018.06.008. Epub 2018 Jun 19. Mol Ther. 2018. PMID: 30005865 Free PMC article.
Harnessing therapeutic viruses as a delivery vehicle for RNA-based therapy.
Ylösmäki L, Polini B, Carpi S, Martins B, Smertina E, Feola S, Fusciello M, Peltonen K, Nieri P, Ylösmäki E, Cerullo V. Ylösmäki L, et al. Among authors: martins b. PLoS One. 2019 Oct 23;14(10):e0224072. doi: 10.1371/journal.pone.0224072. eCollection 2019. PLoS One. 2019. PMID: 31644552 Free PMC article.
Artificially cloaked viral nanovaccine for cancer immunotherapy.
Fusciello M, Fontana F, Tähtinen S, Capasso C, Feola S, Martins B, Chiaro J, Peltonen K, Ylösmäki L, Ylösmäki E, Hamdan F, Kari OK, Ndika J, Alenius H, Urtti A, Hirvonen JT, Santos HA, Cerullo V. Fusciello M, et al. Among authors: martins b. Nat Commun. 2019 Dec 17;10(1):5747. doi: 10.1038/s41467-019-13744-8. Nat Commun. 2019. PMID: 31848338 Free PMC article.
Exploiting Preexisting Immunity to Enhance Oncolytic Cancer Immunotherapy.
Tähtinen S, Feola S, Capasso C, Laustio N, Groeneveldt C, Ylösmäki EO, Ylösmäki L, Martins B, Fusciello M, Medeot M, Tagliamonte M, Chiaro J, Hamdan F, Peltonen K, Ranki T, Buonaguro L, Cerullo V. Tähtinen S, et al. Among authors: martins b. Cancer Res. 2020 Jun 15;80(12):2575-2585. doi: 10.1158/0008-5472.CAN-19-2062. Epub 2020 Feb 27. Cancer Res. 2020. PMID: 32107211
Patient-Derived Organoids for Precision Cancer Immunotherapy.
Grönholm M, Feodoroff M, Antignani G, Martins B, Hamdan F, Cerullo V. Grönholm M, et al. Among authors: martins b. Cancer Res. 2021 Jun 15;81(12):3149-3155. doi: 10.1158/0008-5472.CAN-20-4026. Epub 2021 Mar 9. Cancer Res. 2021. PMID: 33687948 Review.
GAMER-Ad: a novel and rapid method for generating recombinant adenoviruses.
Hamdan F, Martins B, Feodoroff M, Giannoula Y, Feola S, Fusciello M, Chiaro J, Antignani G, Grönholm M, Ylösmäki E, Cerullo V. Hamdan F, et al. Among authors: martins b. Mol Ther Methods Clin Dev. 2021 Feb 4;20:625-634. doi: 10.1016/j.omtm.2021.01.014. eCollection 2021 Mar 12. Mol Ther Methods Clin Dev. 2021. PMID: 33718513 Free PMC article.
Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform.
Ylösmäki E, Ylösmäki L, Fusciello M, Martins B, Ahokas P, Cojoc H, Uoti A, Feola S, Kreutzman A, Ranki T, Karbach J, Viitala T, Priha P, Jäger E, Pesonen S, Cerullo V. Ylösmäki E, et al. Among authors: martins b. Mol Ther Oncolytics. 2021 Feb 10;20:459-469. doi: 10.1016/j.omto.2021.02.006. eCollection 2021 Mar 26. Mol Ther Oncolytics. 2021. PMID: 33718594 Free PMC article.
448 results